Form 4: Core Scientific Director Receives Equity Grant

Core Scientific director Eric Stanton Weiss was granted 18,575 restricted stock units, aligning his interests with long-term shareholder value.

Summary

• Eric Stanton Weiss, a Director of Core Scientific, Inc. (CORZ), acquired 18,575 shares of Common Stock.
• The acquisition was an RSU (Restricted Stock Unit) grant, with a transaction price of $0 per share.
• Following this transaction, Eric Stanton Weiss beneficially owns 245,262 shares of Common Stock directly.
• The RSUs are scheduled to vest in full on February 3, 2027, contingent upon Mr. Weiss continuing his service as a non-employee director to the Issuer on that date.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as it represents a routine equity grant that aligns director interests with long-term shareholder value through performance-based compensation.

Positives

• The grant of restricted stock units to a director aligns management's long-term interests with those of shareholders, promoting sustained performance.

Risks

• The vesting of the restricted stock units is conditional on the Reporting Person's continued service as a non-employee director until February 3, 2027.

Future Outlook

The restricted stock units are set to vest on February 3, 2027, subject to the director's continued service.

Industry Context

StockSavvy.ai notes that equity grants, such as Restricted Stock Units, are a common form of compensation for non-employee directors across various industries, including technology and digital infrastructure. This practice is widely adopted to align the interests of directors with the long-term performance and shareholder value of the company.

Comparison to Industry Standards

• RSU grants for non-employee directors are a standard compensation practice, comparable to those observed in other publicly traded technology and blockchain infrastructure companies like Marathon Digital Holdings (MARA) or Riot Platforms (RIOT), where equity-based incentives are used to retain talent and align interests.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial incentives with the company's long-term performance, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• Continued service of Eric Stanton Weiss as a non-employee director until February 3, 2027, for the RSUs to vest.

Key Dates

Recommendation

This Form 4 reports a routine equity grant to a non-employee director, which is a standard compensation practice. While it aligns the director's interests with shareholders, it does not provide new fundamental information to alter an investment thesis, thus a 'hold' recommendation is appropriate.

Keywords

Core Scientific, CORZ, Form 4, Restricted Stock Unit, RSU, Equity Grant, Director Compensation, Insider Transaction